SCHEMBL23640469

SCHEMBL23640469

O=C1CC[C@H](c2noc3ccc4ccccc4c23)C(=O)N1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 19/20 0.59
CRBN Q96SW2 19/20 0.59
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23640033 1.00 DDB1 (0.59) DDB1CRBNIDO1
SCHEMBL24302284 1.00 DDB1 (0.59) DDB1CRBNIDO1
SCHEMBL24938749 0.85 DDB1 (0.45) DDB1CRBNIDO1
SCHEMBL23640504 0.84 DDB1 (0.42) DDB1CRBNIDO1
SCHEMBL23640481 0.84 DDB1 (0.41) DDB1CRBNIDO1
SCHEMBL23640500 0.84 DDB1 (0.42) DDB1CRBNIDO1
SCHEMBL23640488 0.84 IDO1 (0.44) DDB1CRBNIDO1
SCHEMBL24303034 0.84 CRBN (0.41) DDB1CRBN
SCHEMBL23639961 0.84 DDB1 (0.52) DDB1CRBN
SCHEMBL23640324 0.84 IDO1 (0.44) DDB1CRBNIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
EP-3848367-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 DDB1 333/4885CRBN 1/4885IDO1 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.